Morning Trend | LUYE PHARMA retraces to the stage low point, can sector linkage change the weakness?

Luye Pharma (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning bearish, indicating ongoing market selling pressure. On the fundamental side, although Luye Pharma has launched some new drugs, the industry as a whole is entering a complex phase characterized by stricter policy regulation, price reductions in medical insurance, and high R&D expenditures, which affects performance improvement in the short term due to various uncertainties. The overall performance of the pharmaceutical sector has recently seen a decrease in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas. In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term capital outflows. Luye Pharma is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, making both rises and falls likely to trigger sector resonance. For future trends, attention should be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if there is capital support that leads to a reversal of indicators, there may be a technical rebound in the short term. Investors should strictly control risks, primarily adopting a wait-and-see approach when the bottom is unclear, and if making tentative layouts, set appropriate stop-loss levels